NCT04197999

A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer

A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 4 (actual)
• Sponsor: GlycoMimetics Incorporated · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This trial is being conducted to investigate the safety, tolerability, pharmacokinetics (the effect the body has on the drug), and pharmacodynamics (the effect the drug has on the body) of GMI-1359 when given with standard-of-care treatment to subjects with HR+ metastatic breast cancer.

Conditions

• HR+ Metastatic Breast Cancer
• Breast Cancer
• Breast Cancer Metastatic

Interventions

Type	Name	Description
DRUG	GMI-1359	Injection 10 mg/mL

Timeline

• Start date: 2019-11-21
• Primary completion: 2021-08-25
• Completion: 2021-08-25
• First posted: 2019-12-13
• Last updated: 2022-03-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study